A phase II trial of combination of CPTI-11 and cisplatin for advanced non-small cell lung cancer

British Journal of Cancer

Volumn 78, Issue 2, 1998, Pages 251-256

  Masuda, N ^a   Fukuoka, M ^a   Fujita, A ^b   Kurita, Y ^c   Tsuchiya, S ^d   Nagao, K ^e   Negoro, S ^f   Nishikawa, H ^g   Katakami, N ^h   Nakagawa, K ^a   Niitani, H ⁱ  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b Minami ichijo Hospital   (Japan)

^c Niigata Cancer Center   (Japan)

^d Shibukawa Medical Center   (Japan)

^e CHIBA UNIVERSITY   (Japan)

^f Osaka Municipal Momoyama Hospital   (Japan)

^g TONEYAMA NATIONAL HOSPITAL   (Japan)

^h KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

ⁱ NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cisplatin; Irinotecan; Non small cell lung cancer; Phase II trial

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; EATING DISORDER; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN CELL; ILEUS; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 7144256258     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.473     Document Type: Article

References (35)

1. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P and Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhoea. J Natl Cancer Inst 86: 446-449
2. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y and Okada K (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569
3. Bunn PA (1992) The expanding role of cisplatin in the treatment of non-small cell lung cancer? Semin Oncol 16: 10-21
4. Cellerino R, Tummarello D and Piga A (1990) Chemotherapy or not in advanced non-small cell lung cancer? Lung Cancer 6: 99-109
5. Donnadieu N, Paesmans M and Seulier JP (1991) Chemotherapy of non-small-cell lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer 7: 243-253
6. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S and Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20
7. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A. Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Welte K and Souza L (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414-1422
8. Ginsberg RJ, Kris MG and Armstrong JG (1993) Cancer of the lung. In Cancer: Principle and Practice of Oncology. Devita VT, Hellman S and Rosenberg SA (eds). pp. 673-723. Lippincolt: Philadelphia
9. Gottlieb J and Drewinko B (1975) Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 59: 621-628
10. Grilli R, Oxman A and Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer. How much benefit is enough? Clin Oncol 11: 1866-1872
11. Hong WK and Bromer R (1983) Chemotherapy in head and neck cancer. N Engl J Med 308: 75-59.
12. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M and DeVore III RF (1996) Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 2054-2060
13. Kaplan E and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
14. Kudoh S, Takada M, Masuda N, Nakagavva K, Itoh K, Kusunoki Y, Negoro S, Matsui K, Takifuji N, Morino H and Fukuoka M (1993) Enhanced antitumor efficacy of a combinalion of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor venografts. Jpn J Cancer Res 84: 203-207
15. Kunimoto T, Nittta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T. Sawada S, Miyasaka T and Mutai M (1987) Antitumour activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonylovy-camptothecin, a novel water-soluble derivative of camptothecin. against murine tumours. Cancer Res 47: 5944-5947
16. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S and Ozols RF (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 13: 1860-1870
17. Lilenbaum R and Green M (1993) Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11: 1391-1402
18. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K and Takada M (1992a) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225-1229
19. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K and Kishimoto S (1992b) CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10: 1775-1780
20. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, Nakagawa K, Tamanoi M, Nitta T, Hirashima T, Negoro S and Takada M (1993) Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung Cancer. Br J Cancer 68: 777-782
21. Matsuzaki T, Yokokura T, Mutai M and Tsuruo T (1988) Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin. CPT-11. in mice. Cancer Chemother Pharmacol 21: 308-312
22. Mountain CF (1986) A new international staging system for lung cancer. Chest 89: 225S-233S
23. Negoro S, Fukuoka M, Masoda N, Takada M, Kusunoki Y, Matsui K, Takifuji N. Kudoh S, Niitani H and Taguchi T (1991a) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin. in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168
24. Negoro S, Fukuoka M, Niitani H and Taguchi T (1991b) Phase II study of CPT-11. new camptothecin derivative, in small cell lung cancer (SCLC). Proc Ant Soc Clin Oncol 10: 241
25. Noda K, Takeuchi S, Yakushiji M and CPT-11 study group on gynecologic Malignancy iJ (1991) Late phase II study of CPT-11. new camptothecin derivative. in cervical and ovarian carcinoma. Proc World Cong Gynecol Obstet 13: 279
26. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899-909
27. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S and Ota K (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8: 1907-1912
28. Pirker R, Krajnik G, Zöchbauer S, Malayeri R, Kneussl M and Huber H (1995) Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 6: 833-835
29. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M and Taguchi T (1993) Phase II study of CPT-11. a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11: 909-913
30. Souquet PJ, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Qunoix E, Rapp E, Tumarello D, Williams J, Woods BI and Bernard JP (1993) Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 342: 19-21
31. Splinter TAW (1991) Response rate as criterion to evaluate chemotherapy in non-small cell lung cancer. Lung Cancer 7: 91-104
32. Tacheuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T, Tanizawa O, Sugawa T, Umesaki N, Sekiba T, Aono T, Nakano H, Noda K, Shiota M, Yakushiji M, Sugiyama T, Hashimoto M. Yamaji A, Takamizawa H, Sonoda T, Takeda Y, Tomoda Y, Ohta M, Ozaki M. Hirabayashi K, Hiura M, Hatae M, Nishigaki K and Taguchi T (1991) A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Gan To Kagakuryoho 18: 1681-1689
33. Tsuruo T, Matsuzaki T, Matsushita M, Saito H and Yokokura T (1988) Antitumour effect of CPT-11, a new derivative of camptothecin. against pleiotropic drug-resistant tumours in vitro and in vivo. Cancer Chemother Pharmacol 21: 71-74
34. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. World Health Organization: Geneva
35. Zwelling L and Kohn K (1979) Mechanism of action of cisdichlorodiammineplatinum (II). Cancer Treat Rep 63: 1439-1444